Targeted protein degradation represents a cutting-edge approach in the field of biotechnology, offering a promising strategy to manipulate protein function by specifically targeting and catalyzing protein degradation. While traditional small molecule inhibitors have limitations in targeting undruggable proteins due to their restricted molecular shapes, the emergence of protein degrons has revolutionized the toolbox of protein function regulators. These degrons work by catalyzing protein degradation through ubiquitination, initiating the natural protein degradation pathway and providing a novel way to control protein fate with precision.
The collection of articles on targeted degradation covers a wide range of innovative approaches, including proteolysis-targeting chimeras (PROTAC), lysosome-targeting chimeras (LYTAC), macroautophagy degradation targeting chimeras (MADTAC), degradative nanostructures, and other formats of protein degrons. Beyond the development of these formats, the collection also delves into mechanism investigations, customized targeting strategies, and applications in new disease models. This comprehensive exploration aims to advance our understanding of targeted degradation and its potential implications across various scientific disciplines.
Dr. David Dougan from La Trobe University in Melbourne, Australia, is a prominent researcher focusing on AAA+ proteases and protein homeostasis. His work centers on understanding how these proteases recognize different substrates and the role of specialized cofactors in influencing substrate binding. Dr. Dougan’s expertise contributes significantly to the field of protein degradation and has been recognized through his editorial role in Scientific Reports since 2019.
Dr. Shiqing Xu, an Assistant Professor at Texas A&M University in the United States, specializes in developing innovative synthetic methodologies and therapeutic approaches for biological and medical challenges. His research involves creating small-molecule probes, inhibitors, and degraders for drug discovery, showcasing his dedication to advancing the field of targeted protein degradation. Dr. Xu’s contributions as an Editorial Board Member of Scientific Reports since 2023 highlight his commitment to scientific excellence and innovation.
Dr. Yujun Zhao, a principal investigator at the Shanghai Institute of Materia Medica in China, focuses on modulating disease-related protein interactions and kinases using novel small molecules like PROTACs and molecular glues. His research aims to develop covalent and reversible inhibitors to target disease pathways effectively. As an Editorial Board Member of Scientific Reports since 2024, Dr. Zhao plays a crucial role in shaping the discourse on targeted protein degradation and its applications in therapeutic interventions.
In a rapidly evolving field where precision and specificity are paramount, targeted protein degradation offers a promising avenue for manipulating cellular function with unprecedented accuracy. By harnessing the power of degrons and innovative degradation formats, researchers worldwide are exploring new frontiers in drug discovery, disease modeling, and therapeutic interventions. The collaborative efforts of experts like Dr. Dougan, Dr. Xu, and Dr. Zhao underscore the significance of targeted degradation in shaping the future of biotechnology and advancing our ability to modulate protein function with precision and efficacy.
- Targeted protein degradation presents a groundbreaking approach to manipulating protein function with precision.
- Degraders catalyze protein degradation through ubiquitination, offering new pathways to control protein fate.
- Research efforts in targeted degradation span various innovative formats and customized targeting strategies.
- Experts like Dr. Dougan, Dr. Xu, and Dr. Zhao play pivotal roles in advancing the field of protein degradation and its applications in drug discovery and disease therapeutics.
Read more on nature.com